Graham Capital Management L.P. Boosts Stock Position in Natera, Inc. $NTRA

Key Points

• Graham Capital Management L.P. increased its stake in Natera, Inc. by 78.4% during Q1, now holding shares valued at $880,000.
• Natera reported a 32.2% revenue growth year-over-year, bringing in $546.60 million, although it missed earnings estimates with an EPS of ($0.74).
• Institutional investors have a significant presence in Natera, owning 99.90% of the company's stock, with various firms increasing their positions in the past quarter.

Graham Capital Management L.P. grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 78.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,220 shares of the medical research company's stock after buying an additional 2,733 shares during the period. Graham Capital Management L.P.'s holdings in Natera were worth $880,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HighPoint Advisor Group LLC boosted its holdings in shares of Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock worth $308,000 after buying an additional 468 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after buying an additional 740 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after buying an additional 207 shares in the last quarter. Comerica Bank boosted its holdings in shares of Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock worth $19,954,000 after buying an additional 27,379 shares in the last quarter. Finally, Teza Capital Management LLC acquired a new position in shares of Natera during the fourth quarter worth approximately $221,000. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Cowen reaffirmed a "buy" rating on shares of Natera in a research report on Friday, August 8th. Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Piper Sandler restated an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company's stock. According to data from MarketBeat, Natera has an average rating of "Buy" and an average target price of $194.00.

Natera Stock Down 0.4%

Shares of NASDAQ NTRA traded down $0.63 during trading on Monday, reaching $167.39. The company had a trading volume of 841,017 shares, compared to its average volume of 1,479,647. Natera, Inc. has a 12-month low of $114.62 and a 12-month high of $183.00. The stock has a market cap of $22.97 billion, a PE ratio of -87.64 and a beta of 1.68. The business's 50-day moving average is $154.35 and its 200 day moving average is $153.68.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the company earned ($0.30) earnings per share. The company's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the sale, the chief financial officer owned 65,430 shares of the company's stock, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the transaction, the insider owned 130,205 shares of the company's stock, valued at $21,714,287.85. This represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,423 shares of company stock worth $9,117,416 over the last ninety days. 5.63% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.